A study published in the journal Science on Thursday found that mice given two doses of psilocybin were protected against nerve damage caused by chemotherapy for up to six cycles of treatment. [1]
In a study published in Science in 2026, researchers at The University of Texas MD Anderson Cancer Center reported that psilocybin administered before chemotherapy prevented the onset of chemotherapy-induced peripheral neuropathy in preclinical models, even across repeated chemotherapy cycles. [2] The MD Anderson researchers found that psilocybin protects peripheral nerves through serotonin 5-HT2A receptors by preserving mitochondrial trafficking and energy delivery at nerve endings. [3] Patrick Dougherty, a professor at the University of Texas MD Anderson Cancer Center, stated that this is the first time psilocybin has been used as a neuroprotective agent. [4]
Researchers plan to begin a clinical trial in about a month to test the hypothesis in patients with colorectal, breast, and head and neck cancers undergoing chemotherapy. [5] The research team discovered that psilocybin helps maintain the movement of mitochondria along microtubules in nerve cells, which are attacked by chemotherapy. [6] Blocking the serotonin 5-HT2A pathway reversed psilocybin's neuroprotective effects, while a non-hallucinogenic compound activating the same receptor produced protection similar to psilocybin. [7]
In the preclinical models, two doses of psilocybin given before chemotherapy prevented hypersensitivity to cold, protected sensory nerve endings, and preserved touch sensation, while maintaining chemotherapy's antitumor activity. [8]Un estudio publicado en la revista Science el jueves encontró que los ratones que recibieron dos dosis de psilocibina estuvieron protegidos contra el daño nervioso causado por la quimioterapia hasta por seis ciclos de tratamiento. [1]
En un estudio publicado en Science en 2026, investigadores del Centro de Cáncer MD Anderson de la Universidad de Texas informaron que la psilocibina administrada antes de la quimioterapia previno la aparición de neuropatía periférica inducida por quimioterapia en modelos preclínicos, incluso a través de ciclos repetidos de quimioterapia. [2] Los investigadores de MD Anderson encontraron que la psilocibina protege los nervios periféricos a través de los receptores de serotonina 5-HT2A al preservar el tráfico mitocondrial y la entrega de energía en las terminaciones nerviosas. [3] Patrick Dougherty, profesor del Centro de Cáncer MD Anderson de la Universidad de Texas, declaró que esta es la primera vez que la psilocibina se utiliza como agente neuroprotector. [4]
Los investigadores planean comenzar un ensayo clínico en aproximadamente un mes para probar la hipótesis en pacientes con cáncer colorrectal, de mama y de cabeza y cuello que reciben quimioterapia. [5] El equipo de investigación descubrió que la psilocibina ayuda a mantener el movimiento de las mitocondrias a lo largo de los microtúbulos en las células nerviosas, que son atacadas por la quimioterapia. [6] El bloqueo de la vía de la serotonina 5-HT2A revirtió los efectos neuroprotectores de la psilocibina, mientras que un compuesto no alucinógeno que activa el mismo receptor produjo una protección similar a la psilocibina. [7]
En los modelos preclínicos, dos dosis de psilocibina administradas antes de la quimioterapia previnieron la hipersensibilidad al frío, protegieron las terminaciones nerviosas sensoriales y preservaron la sensación táctil, mientras mantenían la actividad antitumoral de la quimioterapia. [8]
Proof8 sources · 2 publishers
What this stands on
A study published in the journal Science on Thursday found that mice given two doses of psilocybin were protected against nerve damage caused by chemotherapy for up to six cycles of treatment. · Scientific American
In a study published in Science in 2026, researchers at The University of Texas MD Anderson Cancer Center reported that psilocybin administered before chemotherapy prevented the onset of chemotherapy-induced peripheral neuropathy in preclinical models, even across repeated chemotherapy cycles. · Medical Xpress
The MD Anderson researchers found that psilocybin protects peripheral nerves through serotonin 5-HT2A receptors by preserving mitochondrial trafficking and energy delivery at nerve endings. · Medical Xpress
Patrick Dougherty, a professor at the University of Texas MD Anderson Cancer Center, stated that this is the first time psilocybin has been used as a neuroprotective agent. · Scientific American
Researchers plan to begin a clinical trial in about a month to test the hypothesis in patients with colorectal, breast, and head and neck cancers undergoing chemotherapy. · Scientific American
The research team discovered that psilocybin helps maintain the movement of mitochondria along microtubules in nerve cells, which are attacked by chemotherapy. · Scientific American
Blocking the serotonin 5-HT2A pathway reversed psilocybin's neuroprotective effects, while a non-hallucinogenic compound activating the same receptor produced protection similar to psilocybin. · Medical Xpress
In the preclinical models, two doses of psilocybin given before chemotherapy prevented hypersensitivity to cold, protected sensory nerve endings, and preserved touch sensation, while maintaining chemotherapy's antitumor activity. · Medical Xpress
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Thursday, September 3, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.